| 4941L | - | National Wilms Tumor Late Effects Study |
| 9346 | - | Hepatoblastoma Biology Study and Tissue Bank |
| 9900 | - | ALinC 17, Classification (C), B-Precursor Induction Treatment (I) Protocol. |
| 9904 | - | ALinC 17 Treatment for Patients with Low Risk Acute Lymphoblastic Leukemia - A Pediatric Oncology Group Phase III Study |
| 9905 | - | ALinC 17: Protocol for Patients with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL): A Phase III Study |
| 9907 | - | ALinC 17 Cytogenetics Protocol - A Pediatric Oncology Group Non-Therapeutic Study |
| 99701 | - | A Pilot Study of Concurrent Carboplatin, Vincristine and Radiotherapy Followed By Adjuvant Chemotherapy in Patients With Newly Diagnosed High-Risk Central Nervous System Embryonal Tumors |
| 99703 | - | A Pilot Study of Intensive Chemotherapy with Peripheral Stem Cell Support for Infants with Malignant Brain Tumors |
| A0003 | - | Phase I Trial and Pharmacokinetic Study of Arsenic Trioxide in Pediatric Patients with Refractory Leukemia or Lymphoma (T99-0080) |
| A09712 | - | A Phase I Study of Gadolinium Texaphyrin and Involved Field Radiation Therapy for Intrinsic Pontine Glioma of Childhood |
| A2971 | - | Treatment of Children with Down Syndrome and Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Transient Myeloproliferative Disorder. |
| A3961 | - | Treatment for Infants and Children with Intermediate Risk Neuroblastoma |
| A3973 | - | A Randomized Study of Purged vs. Unpurged PBSC Transplant Following Dose Intensive Induction Therapy for High Risk NBL |
| A5971 | - | A Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma |
| A9952 | - | Chemotherapy For Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old |
| AADM01P1 | - | Protocol for Registration and Consent to the Childhood Cancer Research Network: A limited Institution Pilot |
| AALL0031 | - | A Children's Oncology Group Pilot Study for the Treatment of Very High Risk Acute Lymphoblastic Leukemia in Children and Adolescents |
| AALL00P2 | - | T-CELL PILOT PROTOCOL. The Use of Modified BFM +/- Compound 506U78 (NSC# 686673) in an Intensive Chemotherapy Regimen for the Treatment of T-Cell Leukemia |
| AALL01B1 | - | Multiparameter Flow Cytometry for Assessment of Early Marrow Response in Pediatric ALL: A Companion Study to CCG-1991 |
| AALL01P1 | - | A Study of Modified Augmented BFM Therapy for Infants with Acute Lymphoblastic Leukemia |
| AALL01P2 | - | Intensive Induction Therapy for Children with Acute Lymphoblastic Leukemia who Experience a Bone Marrow Relapse |
| AALL02P2 | - | Treatment of Late Isolated Extramedullary Relapse from Acute Lymphoblastic Leukemia (ALL) (Initial CRI = 18 months) |
| AAML00P2 | - | A Dose Finding Study of the Safety of Gemtuzumab Ozogamicin Combined with Conventional Chemotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia |
| AAML0122 | - | Phase II Window Evaluation of the Farnesyl Transferase Inhibitor R115777 followed by 13-cis Retinoic Acid, Cytosine Arabinoside, and Fludarabine, Plus Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia |
| AAML0123 | - | A Phase II Study of Gleevec in Ph+ Chronic Phase Chronic Myelogenous Leukemia |
| AB9804 | - | Clinical and Biological Predictors of Therapy-Related Leukemia |
| ABTR01B1 | - | A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors |
| ACCL0131 | - | Assessment of Clinical and Neuroradiologic Evidence of Methotrexate Leukoencephalopathy in Children Treated on POG 9605 and 9201 |
| ACCL01P3 | - | Differences in Parental Caregiving Demands in Childhood Acute Lymphoblastic Leukemia by Length of Infusion Therapy |
| ACNS0121 | - | A Phase II Trial of Conformal RT for Pediatric Patients with Localized Ependymoma, Chemotherapy prior to 2nd Surgery for Incompletely Resected Ependymoma and Observations for Completely Resected, Differentiated, Supratentorial Ependymoma |
| ACNS0126 | - | A Phase II Study of Temozolomide in the Treatment of Children With High-Grade Gliomas |
| ACNS0226 | - | A Phase II Study of R115777 (ZARNESTRA) (NSC# 702818, IND# 58359) in Children with Recurrent or Progressive High Grade Glioma, Medulloblastoma/PNET or Brainstem Glioma |
| ACNS0231 | - | A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence with a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy with Peripheral Blood Stem Cell (PBSC) Support |
| ACNS02B1 | - | Pre-clinical Pharmacology in Surgical Brain Tumor Specimens |
| ACNS02B2 | - | Preclinical Analysis of CD 155 and an Intergeneric Poliovirus in Pediatric Brain Tumor Specimens |
| ADVL0013 | - | A Phase I Study of 90YTTRIUM-IBRITUMOMAB TIUXETAN (IDEC-Y2B8, YTTRIUM (90)-ANTI-CD20) Preceded by Rituximab (IDEC-C2B8) in Children with Recurrent/Refractory CD20 Positive Lymphoma |
| ADVL0016 | - | A Phase I Study of ZD1839 IressaTM, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Children with Refractory Solid Tumors |
| ADVL0023 | - | A Phase II Study of Docetaxel (Taxotere) (NSC#628503) in Children with Refractory Leukemias |
| ADVL0114 | - | Phase I Trial of Decitabine (DAC) (IND#50733) in Children with Relapsed or Refractory Acute Leukemia |
| ADVL0116 | - | A Phase I Trial and Pharmacokinetic Study of R115777 in Pediatric Patients with Refractory Leukemias |
| ADVL0122 | - | A Phase II Study of Gleevec (Imatinib mesylate, NSC 716051 formerly STI571) in Children with Refractory or Relapsed Solid Tumors |
| ADVL0211 | - | A Phase I Trial of G3139 (BCL-2 ANTISENSE, NSC# 683428, IND# 58842) Combined with Cytotoxic Chemotherapy in Relapsed Childhood Solid Tumors |
| ADVL0212 | - | A Phase I Study of Depsipeptide (NSC#630176, IND# 51810) in Pediatric Patients with Refractory Solid Tumors |
| ADVL04P2 | - | A Phase 1/2 Pilot Study Of Chemoimmunotherapy With Epratuzumab For Children With Relapsed Cd22-Positive Acute Lymphoblastic Leukemia |
| AEWS0031 | - | Trial of Chemotherapy Intensification through Interval Compression in Ewing's Sarcoma and Related Tumors |
| AEWS02B1 | - | A Groupwide Biology and Banking Study for Ewing Sarcoma |
| AEWS0331 | - | European Ewing Tumor Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99) |
| AGCT0132 | - | A Phase III Study of Reduced Therapy in the Treatment of Children with Low and Intermediate Risk Extracranial Germ Cell Tumors |
| AHOD0031 | - | A Phase III Study of Dose-Intensive, Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate Risk Hodgkin Disease |
| AHOD00P1 | - | A Pilot Study of Re-Induction Chemotherapy with Ifosfamide, and Vinorelbine (IV) in Children with Refractory/Relapsed Hodgkin Disease |
| AHOD0121 | - | A Phase II/III Study of Immunomodulation After High Dose Myeloablative Therapy with Autologous Stem Cell Rescue for Refractory/Relapsed Hodgkin Disease |
| ALTE02C1 | - | Quality of Life in Children Who Survived Neuroblastoma |
| ALTE04N1 | - | Health-Related Outcomes for Hodgkin Disease Survivors |
| ANBL0032 | - | Phase III Randomized Study of Chimeric Anti-GD2 in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue |
| ANBL00B1 | - | Neuroblastoma Biology Studies |
| ANBL00P1 | - | A Pilot Study of Tandem High Dose Chemotherapy with Stem Cell Rescue Following Induction Therapy in Children with High Risk Neuroblastoma |
| ANBL00P2 | - | Perinatal Neuroblastoma: Expectant Observation. A Children's Oncology Group Pilot Study |
| ANBL0321 | - | Phase II Study of Fenretinide in Pediatric Patients with Resistant or Recurrent Neuroblastoma |
| ANHL0121 | - | A Phase II Study of Rituximab with Combination Chemotherapy in Relapsed or RefractorySNCLL, B-LCL, B-ALL. |
| ANHL0131 | - | A Phase III Study of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma ALCL with Standard APO Adriamycin, Prednisone, Vincristine versus Consolidation with a Regimen Including Vinblastine |
| AOST0121 | - | A Groupwide Phase II Study of Trastuzumab ( Herceptin) in Metastatic Osteosarcoma Patients with Tumors that Overexpress HER2 |
| ARST0121 | - | A Groupwide Randomized Phase II Window Study of Two Different Schedules of Irinotecan and Pilot Assessment of Safety and Efficacy of Tirapazamine Combined with Multiagent Chemotherapy for First Relapse or Progressive Disease in Rhabdomyosarcoma and Related Tumors |
| ARST03P1 | - | ARST03P1 - A Pilot Phase II Study for Children with Infantile Fibrosarcoma |
| AS9801 | - | AS9801 - A Study of Second Malignant Neoplasms following Childhood Cancer |
| ASCT0031 | - | Phase III Trial of Hydroxychloroquine + Standard Therapy for Chronic Graft-Versus-Host-Disease |
| B24 | - | Molecular Analysis of Preleukemic and Leukemic Marrow from Patients With Monosomy 7 and 7q- |
| B945 | - | The Genetic Epidemiology of 11q23 Leukemia in the Young |
| B947 | - | Protocol for Collection of Biology Specimens for Research Studies |
| B957 | - | Genetic Etiology of Acute Leukemia in Down Syndrome |
| B961 | - | Prognostic Significance of Ki-67 Proliferative Index Utilizing the MIB-1 Antibody in Low Grade Gliomas in Young Children |
| B971 | - | Molecular Cytogenetic Determination of Prognostic Parameters in Childhood Primitive Neuroectodermal Tumor |
| B972 | - | Immune Status and Activation in Children Participating in CCG-2961, A Phase III Trial in Children with Untreated AML or Myelodysplastic Syndrome. |
| B975 | - | The Relationship Between p53 Mutations and Proliferation Index and Prognosis in Malignant Gliomas of Childhood |
| B9802 | - | A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children with Leukemia |
| C9710 | - | Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy With or Without Arsenic Trioxide (AS2O3) (NSC # 706363) as Initial Consolidation Therapy Followed by Maintenance Therapy with Intermittent Tretinoin Versus Intermittent Tretinoin Plus Mercaptopurine and Metotrexate for Patients with Untreated Acute Promyelocytic Leukemi |
| D9602 | - | Actinomycin D and VCR with or without CPM and RT, for Newly Diagnosed Patients with Low-Risk Embryonal/Botryoid Rhabdomyosarcoma: IRS-V Protocol |
| D9802 | - | D9802, A Phase II "Up-Front Window Study" of Irinotecan (CPT-11) Combined with Vincristine followed by Multimodal, Multiagent, Therapy for Selected Children and Adolescents with Newly Diagnosed Stage 4/Clinical Group IV Rhabodomyosarcoma: An IRS-V/STS Study |
| D9803 | - | Randomized Study of VCR, Actinomycin-D, and CPM (VAC) vs. VAC alternating with VCR, Topotecan, and CPM (VTC) for Patients withttp://dev.curesearch.org/WorkArea/edit.aspxh Intermediate Risk RMS |
| D9902 | - | D9902, A COG Protocol for Collecting and Banking Soft Tissue Sarcoma Specimens |
| L9704 | - | Quality of Life Following Successful Therapy of AML: A Comparison of Marrow Transplant and Chemotherapy. |
| P9407 | - | Induction Intensification and Allogeneic Bone Marrow Transplant in Infant ALL: A Children's Oncology Group Pilot Study |
| P9641 | - | Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma |
| P9645 | - | Phase III Protocol for the Treatment of Children with Hepatoblastoma |
| P9761 | - | A Phase II Trial of Irinotecan in Children with Refractory Solid Tumors |
| P9851 | - | Osteosarcoma Biology Protocol: Companion to Group-Wide Therapeutic Studies |
| P9934 | - | Systemic Chemotherapy, Second Look Surgery and Involved Field Radiation for Children greater than or equal to 8 months and less than or equal to 36 months with Non-metastatic (MO) Medulloblastoma |
| P9962 | - | A Phase II Study of Intrathecal Topotecan (NSC #609699) in Patients with Refractory Meningeal Malignancies |
| P9963 | - | A Phase II Trial of Rebeccamycin Analogue (NSC #655649) in Children with Solid Tumors |
| R9701 | - | Use of Thallium Scintigraphy in Assessing Therapeutic Response of Pediatric Osteogenic Sarcoma to Chemotherapy |
| S0008 | - | Phase III Trial of High Dose Interferon Alpha-2B Versus Cisplatin, Vinblastine, DTIC Plus IL-2 and Interferon in Patients with High Risk Melanomai |
| S9901 | - | Informed Consent in the Children's Cancer Group |
